News Story: Full Text
Sponsored By
Genentech Biooncology
Please Click On The Above Banner For More Details
Braintumor Website


Peregrine Accepted for Poster Presentation of Cotara Trial Data At the Society of Nuclear Medicine (Business Wire)...~~~Phase I/II Evaluation of the Therapeutic Efficacy and Safety of 131I-chTNT-1/B for Treatment of Malignant Tumors.......~~~ Cotara is Peregrine`s Tumor Necrosis Therapy (TNT) drug.......Cotara is currently being studied in a multi-center Phase II study for brain cancer....- Apr 24 8:23 AM ET

IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source:

(Everything below this line is from!)

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557